^
Association details:
| Biomarker: | FGFR1 mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | zotatifin (eFT226) (eIF4A1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors
Published date:
11/24/2021
Excerpt:
In solid tumor models driven by alterations in HER2 or FGFR1/2, downregulation of oncoprotein expression by zotatifin induces sustained pathway-dependent anti-tumor activity resulting in potent inhibition of cell proliferation, induction of apoptosis, and significant in vivo tumor growth inhibition or regression.
DOI:
10.3389/fonc.2021.766298
